771 related articles for article (PubMed ID: 31601267)
1. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
2. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
4. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
5. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
6. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
7. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
Lemstra AW; de Beer MH; Teunissen CE; Schreuder C; Scheltens P; van der Flier WM; Sikkes SA
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):113-118. PubMed ID: 27794030
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
[TBL] [Abstract][Full Text] [Related]
10. Antemortem CSF A
Baiardi S; Abu-Rumeileh S; Rossi M; Zenesini C; Bartoletti-Stella A; Polischi B; Capellari S; Parchi P
Ann Clin Transl Neurol; 2019 Feb; 6(2):263-273. PubMed ID: 30847359
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
13. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
[TBL] [Abstract][Full Text] [Related]
14. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
15. Alterations of CSF cystatin C levels and their correlations with CSF Αβ40 and Αβ42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis.
Zhong XM; Hou L; Luo XN; Shi HS; Hu GY; He HB; Chen XR; Zheng D; Zhang YF; Tan Y; Liu XJ; Mu N; Chen JP; Ning YP
PLoS One; 2013; 8(1):e55328. PubMed ID: 23383156
[TBL] [Abstract][Full Text] [Related]
16. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
Geng C; Tan L; Chen C
Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
19. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
